We are monitoring the impact of COVID-19 on Europe CAR T cell Therapy Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2020
ID: 9989
Share on
Share on

Europe CAR T cell Therapy Market Research Report - By Target Antigen, Products, Application, Country (the United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Size, Share, Trends and Forecast (2020 to 2025)

Pulished: August, 2020
ID: 9989
Pages: 100

Europe CAR T cell Therapy Market (2020 to 2025)

The CAR T cell Therapy Market in Europe is estimated to grow at a remarkable CAGR from 2020 to 2025.

Factors that drive the Europe CAR T cell therapy market are increasing the number of cancer cases, rising occurrence rate of haematological cancer like leukaemia, lymphoma, and multiple myeloma propelling the market growth over the forecast period. Growing investments made by the government and other private organizations are surging the T-cell therapy market growth over the analysis period. Increasing healthcare expenditure and increasing disposable income are fuelling market growth over the forecasting framework.

The cost associated with the CAR T cell therapy market is so expensive and is restraining the market growth to some extent over the forecast timeframe. Also, CAR T cell therapy can cause side-effects post-therapy may also hamper the market growth during the forecast period. Lack of awareness regarding T-cell therapy, particularly in rural areas for the therapy process for cancer, restricts the market growth. Poor reimbursement policies from the governments may hamper the CAR T cell therapy market growth in this region.

This research report on the European CAR T Cell therapy market has been segmented and sub-segmented into the following categories.

  • By Target Antigen: CD20, EGFRV III, CD19, HER2, MESO, CD22, BCMA, GD2, CD30, HER1, and CD33
  • By Application: Multiple Myeloma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse large B-cell lymphoma, and Acute Lymphoblastic Leukemia
  • By Product: Allogeneic and Autologous
  • By Therapies: Axicabtagene ciloleucel (Yescarta) and Tisagenlecleucel (Kymriah)
  • By End User: Cancer Research Centers, Hospitals, Academic and Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Contract Research Organizations
  • By Country: the United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe

Regional Analysis

CAR T cell therapy in the European region is expected to have the fastest growing in the market over the analysis period. The growth is due to factors such as growing awareness related to health disorders and rising support from government organizations.

UK is leading the CAR T cell therapy market of this region due to growing research and development activities. Government initiatives taken for introducing reimbursement policies in support of the poor people are leveling up the market growth in this region over the analysis period. Moreover, an increasing number of cases in the country, advancements in technology for advanced and reliable treatment for cancer diseases, growing pharmaceutical industries, and a rise in the number of clinical studies drive the CAR T cell market growth of the Europe region.

The CAR T cell therapy market in Germany is expected to have the highest growth in the region. The factors stimulating the growth are development within a short period, rising investments among the research institute fueling market growth. Moreover, a growing number of cancer cases in adults and children, an increasing number of clinical trials also enhance growth. Launch of various CAR T-cell therapies and drugs is expected to drive the market growth in the European region.

Countries like France, Spain, Italy, and other countries are likely to have considerable growth in this region over the forecast period.

Key players leading the European CAR T cell therapy market profiled in this report are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Legend Biotech, Sorrento Therapeutics Inc., Kite Pharma, Inc., Immune Therapeutics, Bellicum Pharmaceuticals, Inc. and Pfizer, Inc.

  1. INTRODUCTION
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. RESEARCH METHODOLOGY
    1. Introduction
    2. Research Phases
      1. Secondary Research
      2. Primary Research
      3. Econometric Modelling
      4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. OVERVIEW
    1. Executive Summary
    2. Key Inferences
  4. DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ANALYSIS
    1. Market Drivers
    2. Market Restraints
    3. Key Challenges
    4. Current Opportunities in the Market
  5. MARKET SEGMENTATION
    1. By Target Antigen
      1. CD20
      2. EGFRV III
      3. CD19
      4. HER2
      5. MESO
      6. CD22
      7. BCMA
      8. GD2
      9. CD30
      10. HER1
      11. CD33
      12. Y-o-Y Growth Analysis, By Target Antigen
      13. Market Attractiveness Analysis, By Target Antigen
      14. Market Share Analysis, By Target Antigen
    2. By Application
      1. Multiple Myeloma
      2. Chronic Lymphocytic Leukemia
      3. Mantle Cell Lymphoma
      4. Follicular Lymphoma
      5. Diffuse large B-cell lymphoma
      6. Acute Lymphoblastic Leukemia
      7. Y-o-Y Growth Analysis, By Application
      8. Market Attractiveness Analysis, By Application
      9. Market Share Analysis, By Application
    3. By Product
      1. Allogeneic
      2. Autologous
      3. Y-o-Y Growth Analysis, By Product
      4. Market Attractiveness Analysis, By Product
      5. Market Share Analysis, By Product
    4. By Therapies
      1. Axicabtagene ciloleucel (Yescarta)
      2. Tisagenlecleucel (Kymriah)
      3. Y-o-Y Growth Analysis By Therapies
      4. Market Attractiveness Analysis, By Therapies
      5. Market Share Analysis, By Therapies
    5. By End-User
      1. Cancer Research Centers
      2. Hospitals
      3. Academic and Research Institutes
      4. Pharmaceutical Companies
      5. Biotechnology Companies
      6. Contract Research Organizations
      7. Y-o-Y Growth Analysis, By End User
      8. Market Attractiveness Analysis, By End User
  6. GEOGRAPHICAL ANALYSIS
    1. Introduction
      1. Regional Trends
      2. Impact Analysis
      3. Y-o-Y Growth Analysis
      4. Market Attractiveness Analysis
      5. Market Share Analysis
    2. Europe
      1. Introduction
      2. United Kingdom
      3. Germany
      4. Italy
      5. France
      6. Spain
      7. Rest of Europe
  7. STRATEGIC ANALYSIS
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter's Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. The threat of New Entrants
      4. The Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  8. MARKET LEADERS' ANALYSIS
    1. Mustang Bio, Inc.,
      1. Overview
      2. Products
      3. Financials (subjected to availability based on company type)
      4. Recent Developments
      5. SWOT analysis
      6. Analyst View
    2. Celgene Corporation
    3. Bluebird Bio, Inc.
    4. CARsgen Therapeutics, Ltd.
    5. Novartis International AG
    6. Legend Biotech
    7. Sorrento Therapeutics Inc.
    8. Kite Pharma, Inc.
    9. Immune Therapeutics
    10. Bellicum Pharmaceuticals, Inc.
    11. Pfizer, Inc.
  9. COMPETITIVE LANDSCAPE
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  10. MARKET OUTLOOK AND INVESTMENT OPPORTUNITIES
  11. APPENDIX
    1. List of Tables
    2. List of Figures
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is booming, and to also identify the areas that are still untapped.
  • The segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, vital financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Global CAR T cell Therapy Market, By Target Antigen, From 2020 to 2025 (USD Million)
  2. Europe CD 20 Market, By Region, From 2020 to 2025 (USD Million)
  3. Europe EGFRV III Market, By Region, From 2020 to 2025 (USD Million)
  4. Europe CD 19 Market, By Region, From 2020 to 2025 (USD Million)
  5. Europe HER 2 Market, By Region, From 2020 to 2025 (USD Million)
  6. Europe MESO Market, By Region, From 2020 to 2025 (USD Million)
  7. Europe CD 22 Market, By Region, From 2020 to 2025 (USD Million)
  8. Europe BCMA Market, By Region, From 2020 to 2025 (USD Million)
  9. Europe GD 2 Market, By Region, From 2020 to 2025 (USD Million)
  10. Europe CD 30 Market, By Region, From 2020 to 2025 (USD Million)
  11. Europe HER 1 Market, By Region, From 2020 to 2025 (USD Million)
  12. Europe Global CAR T cell Therapy Market, By Application, From 2020 to 2025 (USD Million)
  13. Europe Multiple Myeloma Market, By Region, From 2020 to 2025 (USD Million)
  14. Europe Chronic Lymphocytic Leukemia Market, By Region, From 2020 to 2025 (USD Million)
  15. Europe Mantle Cell Lymphoma Market, By Region, From 2020 to 2025 (USD Million)
  16. Europe Follicular Lymphoma Market, By Region, From 2020 to 2025 (USD Million)
  17. Europe Diffuse large B-cell Lymphoma Market, By Region, From 2020 to 2025 (USD Million)
  18. Europe Acute Lymphoblastic Leukemia Market, By Region, From 2020 to 2025 (USD Million)
  19. Europe Global CAR T cell Therapy Market, By Product, From 2020 to 2025 (USD Million)
  20. Europe Allogeneic Market, By Region, From 2020 to 2025 (USD Million)
  21. Europe Autologous Market, By Region, From 2020 to 2025 (USD Million)
  22. Europe Global CAR T cell Therapy Market, By Therapies, From 2020 to 2025 (USD Million)
  23. Europe Axicabtagene Ciloleucel (Yescarta) Market, By Region, From 2020 to 2025 (USD Million)
  24. Europe Tisagenlecleucel (Kymriah) Market, By Region, From 2020 to 2025 (USD Million)
  25. Europe Global CAR T cell Therapy Market, By End-User, From 2020 to 2025 (USD Million)
  26. Europe Cancer Reasearch Centers Market, By Region, From 2020 to 2025 (USD Million)
  27. Europe Hospitals Market, By Region, From 2020 to 2025 (USD Million)
  28. Europe Academic and Research institutes Market, By Region, From 2020 to 2025 (USD Million)
  29. Europe Pharmaceutical Companies Market, By Region, From 2020 to 2025 (USD Million)
  30. Europe Biotechnology Companies  Market, By Region, From 2020 to 2025 (USD Million)
  31. Europe Contract Research Organizations Market, By Region, From 2020 to 2025 (USD Million)
  32. U.K. Global CAR T cell Therapy Market, By Target Antigen, From 2020 to 2025 (USD Million)
  33. U.K. Global CAR T cell Therapy Market, By Application, From 2020 to 2025 (USD Million)
  34. U.K. Global CAR T cell Therapy Market, By Product, From 2020 to 2025 (USD Million)
  35. U.K. Global CAR T cell Therapy Market, By Therapies, From 2020 to 2025 (USD Million)
  36. U.K. Global CAR T cell Therapy Market, By End-User, From 2020 to 2025 (USD Million)
  37. Germany Global CAR T cell Therapy Market, By Target Antigen, From 2020 to 2025 (USD Million)
  38. Germany Global CAR T cell Therapy Market, By Application, From 2020 to 2025 (USD Million)
  39. Germany Global CAR T cell Therapy Market, By Product, From 2020 to 2025 (USD Million)
  40. Germany Global CAR T cell Therapy Market, By Therapies, From 2020 to 2025 (USD Million)
  41. Germany Global CAR T cell Therapy Market, By End-User, From 2020 to 2025 (USD Million)
  42. France Global CAR T cell Therapy Market, By Target Antigen, From 2020 to 2025 (USD Million)
  43. France Global CAR T cell Therapy Market, By Application, From 2020 to 2025 (USD Million)
  44. France Global CAR T cell Therapy Market, By Product, From 2020 to 2025 (USD Million)
  45. France Global CAR T cell Therapy Market, By Therapies, From 2020 to 2025 (USD Million)
  46. France Global CAR T cell Therapy Market, By End-User, From 2020 to 2025 (USD Million)
  47. Italy Global CAR T cell Therapy Market, By Target Antigen, From 2020 to 2025 (USD Million)
  48. Italy Global CAR T cell Therapy Market, By Application, From 2020 to 2025 (USD Million)
  49. Italy Global CAR T cell Therapy Market, By Product, From 2020 to 2025 (USD Million)
  50. Italy Global CAR T cell Therapy Market, By Therapies, From 2020 to 2025 (USD Million)
  51. Italy Global CAR T cell Therapy Market, By End-User, From 2020 to 2025 (USD Million)
  52. Spain Global CAR T cell Therapy Market, By Target Antigen, From 2020 to 2025 (USD Million)
  53. Spain Global CAR T cell Therapy Market, By Application, From 2020 to 2025 (USD Million)
  54. Spain Global CAR T cell Therapy Market, By Product, From 2020 to 2025 (USD Million)
  55. Spain Global CAR T cell Therapy Market, By Therapies, From 2020 to 2025 (USD Million)
  56. Spain Global CAR T cell Therapy Market, By End-User, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample